The device would be the first clinical-grade, diagnostic wrist-worn device for long term Afib monitoring
News | Wearables
Clinical Smartwatch Finds Success at Identifying Atrial Fibrillation

December 1, 2023 — As the use of wearable technology grows, smartwatches are marketed across the globe to consumers as a ...

Home December 01, 2023
Home
Mount Sinai Fuster Heart Hospital is one of the world’s top four hospitals in Cardiology/Heart Surgery
News | ACC
Transcatheter Valve Replacement Procedures at the Mount Sinai Hospital Win Highest Eating from Society of Thoracic Surgeons

December 1, 2023 — For the third consecutive year, the Cardiac Catheterization Laboratory at The Mount Sinai Hospital ...

Home December 01, 2023
Home
Researchers have succeeded in restoring lost brain function in mouse models of stroke using small molecules that in the future could potentially be developed into a stroke recovery therapy.
News | Stroke
New Study: Lost Brain Function Restored After Stroke

December 1, 2023 — Researchers have succeeded in restoring lost brain function in mouse models of stroke using small ...

Home December 01, 2023
Home
Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation
News | Atrial Fibrillation
Johnson & Johnson MedTech Acquires Laminar, Inc.

November 30, 2023 — Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a ...

Home November 30, 2023
Home
Japan’s PMDA asked for further details on a number of elements included in BioCardia’s CardiAMP preclinical and clinical packages in order to gain approval.
News | Heart Failure
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 30, 2023
Home
Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks post DSR treatment
News | Heart Failure
Sequana Medical Announces Positive Data from Non-randomized Cohort in US Phase 1/2a MOJAVE Study of DSR 2.0 for Treatment of Heart Failure

November 30, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home November 30, 2023
Home
Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study
News | Cardiovascular Clinical Studies
Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced completion of enrollment in the Indian clinical trial of the TRIA polymer surgical mitral heart valve.
News | Cardiovascular Clinical Studies
Foldax Completes Enrollment in India Clinical Trial Evaluating TRIA Polymer Surgical Mitral Heart Valve

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
Study to enroll 15 acute stroke patients across three U.S. sites
News | Stents
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
Impella Improves Survival and Heart Recovery
News | Cardiovascular Clinical Studies
First Patient Enrolled in Abiomed’s RECOVER IV Randomized Controlled Trial of Impella as a Therapy for AMI Cardiogenic Shock

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast cancer
News | Womens Cardiovascular Health
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, will ...

Home November 28, 2023
Home
A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation
News | Cardiovascular Clinical Studies
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)
News | FDA
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home November 27, 2023
Home
News | Atrial Fibrillation
Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

November 24, 2023 — During the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA ...

Home November 22, 2023
Home
A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has been achieved with the recent U.S. Food & Drug Administration (FDA) approvals of two renal denervation (RDN) systems
News | Artificial Intelligence
Renal HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

November 22, 2023 — Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-powered medical ...

Home November 22, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now